Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02265510
Title An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Incyte Corporation
Indications

Advanced Solid Tumor

Therapies

Gemcitabine

Carfilzomib

Dexamethasone

Lenalidomide

Nab-paclitaxel

Azacitidine

INCB052793

Bortezomib

Age Groups: adult
Covered Countries USA


No variant requirements are available.